Day 1: February 9, 2010 (8:00 am – 5:00 pm)
Day
2: February 10, 2010 (8:00 am – 2:00 pm)
The
National Cancer Policy Forum is holding a public workshop addressing the
widening spectrum of precompetitive collaboration in oncology biomedical
research and development. Over the last decade, biomedical research and drug
development costs have skyrocketed, despite falling productivity evidenced by
increasing drug development timelines and decreasing new molecular entity
approvals. Increased precompetitive collaboration is a potential driver for
innovation and improved productivity. Recent developments in the field of
biomedical research and drug development, including the implementation of
one-on-one consortia, network models, and larger scale consortia highlight the
increasing role that competitive and precompetitive collaboration is assuming
within biomedical research and drug development.
Workshop presentations and discussions will provide a general characterization
of the precompetitive collaboration environment as well as examples of
precompetitive collaboration in science, biomedicine, and oncology. The
concluding panel will be devoted to exploring how we can leverage prior
experiences to facilitate future precompetitive collaboration opportunities.
The Roundtable on Translating Genomic-Based Research for Health will be hosting
a related workshop July 22, 2010 in Washington, D.C.
Confirmed Speakers
· Jill Altshuler, M.B.A., AltshulerGray
· Neal Cohen, M.D., M.P.H., M.S., University of California, San Francisco School
of Medicine
· Gregory Curt, M.D., AstraZeneca and
CEO Roundtable on Cancer Life Sciences Consortium
· Laura Esserman, M.D., M.B.A., UCSF Carol Franc Buck Breast Care Center
· Stephen Friend, M.D., Ph.D., Sage Bionetworks
· Pearl Huang, Ph.D., Merck & Co., Inc.
· Gary Kelloff, M.D., NCI Cancer Imaging Program
· Karim Lakhani, Ph.D., M.S., Harvard Business School
· Mark McClellan, M.D., Ph.D., Brookings Institution’s Engelberg Center for
Health Care Reform
· Bernard Munos, M.B.A., Ph.D., Eli Lilly & Co.
· William Spencer, Ph.D., Chairman Emeritus, SEMATECH
· Joseph Vockley, Ph.D., The Cancer Genome Atlas
· David Wholley, M. Phil., The Biomarkers Consortium
· Thinh Nguyen, J.D., Science Commons
· Bryn Williams-Jones, Pfizer
· Ray Woosley, M.D., Ph.D., Critical Path Institute
Planning Committee
· John Wagner, M.D., Ph.D., Merck & Co., Inc. (Chair)
· Anna Barker, Ph.D., National Cancer Institute
· Stephen Eck, M.D., Ph.D., Eli Lilly & Co.
· Stephen Friend, M.D., Ph.D., Sage Bionetworks
· Geoff Ginsburg, M.D., Ph.D., Duke
University
· Roy Herbst, M.D., Ph.D., MD Anderson
· Sharon Murphy, M.D., IOM Scholar-in-Residence